EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pathway activation model for personalized prediction of drug synergy

Quang Thinh Trac iD, Yue Huang, Tom Erkers, Päivi Östling, Anna Bohlin, Albin Osterroos, Mattias Vesterlund iD, Rozbeh Jafari, Ioannis Siavelis, Helena Backvall, Santeri Kiviluoto, Lukas Orre und 6 weitere

eLife · 03.06.2025 · 13

DOI: 10.7554/elife.100071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, online erschienen am 03.06.2025. Verfasst von Quang Thinh Trac und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Drug Synergism, Precision Medicine, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Cancerfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted monotherapies for cancer often fail due to inherent or acquired drug resistance. By aiming at multiple targets simultaneously, drug combinations can produce synergistic interactions that increase drug effectiveness and reduce resistance. Computational models based on the integration of omics data have been used to identify synergistic combinations, but predicting drug synergy remains a challenge. Here, we introduce Drug synergy Interaction Prediction (DIPx), an algorithm for personalized prediction of drug synergy based on biologically motivated tumor- and drug-specific pathway activation scores (PASs). We trained and validated DIPx in the AstraZeneca-Sanger (AZS) DREAM Challenge human cell-line dataset using two separate test sets: Test Set 1 comprised the combinations already present in the training set, while Test Set 2 contained combinations absent from the training set, thus indicating the model’s ability to handle novel combinations. The Spearman’s correlation coefficients between predicted and observed drug synergy were 0.50 (95% CI: 0.47–0.53) in Test Set 1 and 0.26 (95% CI: 0.22–0.30) in Test Set 2, compared to 0.38 (95% CI: 0.34–0.42) and 0.18 (95% CI: 0.16–0.20), respectively, for the best performing method in the Challenge. We show evidence that higher synergy is associated with higher functional interaction between the drug targets, and this functional interaction information is captured by PAS. We illustrate the use of PAS to provide a potential biological explanation in terms of activated pathways that mediate the synergistic effects of combined drugs. In summary, DIPx can be a useful tool for personalized prediction of drug synergy and exploration of activated pathways related to the effects of combined drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug SynergismPrecision MedicineAntineoplastic AgentsNeoplasmsHumansAlgorithmsComputational BiologyCell Line, Tumor

Stichwörter der Autor:innen

computational biologydrug synergyhumanpathway activation scoreprediction modelsystems biology

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Health Statistics, School of Public Health, Weifang Medical University, Weifang, China.
  • Department of Oncology Pathology, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden.
  • Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
  • Department of Medicine Huddinge, Karolinska Institutet, Unit for Hematology, Karolinska University Hospital Huddinge, Stockholm, Sweden.
  • Department of Medical Sciences, Hematology, Uppsala University Hospital, Uppsala, Sweden.

ORCID-Profile: Quang Thinh Trac, Mattias Vesterlund, Janne Lehtiö, Trung Nghia Vu

Förderung

  • Swedish Research Council
  • Cancerfonden

Zitieren

APA

Trac, Q. T., Huang, Y., Erkers, T., Östling, P., Bohlin, A., Osterroos, A., Vesterlund, M., Jafari, R., Siavelis, I., Backvall, H., Kiviluoto, S., Orre, L., Rantalainen, M., Lehtiö, J., Lehmann, S., Kallioniemi, O., Pawitan, Y., & Vu, T. N. (2025). Pathway activation model for personalized prediction of drug synergy. eLife, 13. https://doi.org/10.7554/elife.100071

Vancouver

Trac QT, Huang Y, Erkers T, Östling P, Bohlin A, Osterroos A, et al. Pathway activation model for personalized prediction of drug synergy. eLife. 2025;13. doi:10.7554/elife.100071

BibTeX
@article{Trac2025,
  author = {Trac, Quang Thinh and Huang, Yue and Erkers, Tom and Östling, Päivi and Bohlin, Anna and Osterroos, Albin and Vesterlund, Mattias and Jafari, Rozbeh and Siavelis, Ioannis and Backvall, Helena and Kiviluoto, Santeri and Orre, Lukas and Rantalainen, Mattias and Lehtiö, Janne and Lehmann, Soren and Kallioniemi, Olli and Pawitan, Yudi and Vu, Trung Nghia},
  title = {Pathway activation model for personalized prediction of drug synergy},
  journal = {eLife},
  year = {2025},
  volume = {13},
  doi = {10.7554/elife.100071}
}
Kostenlos starten →